IPSEN (OTCMKTS:IPSEY) Receives Average Recommendation of “Hold” from Analysts

Shares of IPSEN (OTCMKTS:IPSEY) have been given a consensus rating of “Hold” by the six research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company.

IPSEY has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Zacks Research upgraded shares of IPSEN to a “hold” rating in a report on Friday, May 29th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th.

IPSEN Stock Performance

OTCMKTS IPSEY opened at $49.15 on Thursday. The company has a 50-day simple moving average of $46.45 and a two-hundred day simple moving average of $46.67. IPSEN has a 12-month low of $32.02 and a 12-month high of $51.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).